<DOC>
	<DOCNO>NCT02067767</DOCNO>
	<brief_summary>Abacavir/Lamivudine + Nevirapine ( ABC/3TC + NVP ) effective well tolerable regimen long-term . However regimen comprises 2 pill per day . Abacavir/Lamivudine/Dolutegravir ( ABC/3TC/DTG ) offer simplification single pill per day food constraint , Dolutegravir ( DTG ) advantage Nevirapine ( NVP ) high potency , high genetic barrier resistance , good safety profile . The objective study evaluate virologic safety ( maintenance virologic suppression ) switch ABC/3TC + NVP ABC/3TC/DTG 50 HIV-1 infected adult prolong HIV RNA suppression ABC/3TC + NVP , well clinical laboratory safety . Because nevirapine strong inducer hepatic enzyme , pharmacocinetic ( PK ) assessment perform patient first week switch 24-hours PK subset 10 patient 5 day DTG addition current regimen , switch ABC/3TC/DTG .</brief_summary>
	<brief_title>Multicentric Open-label Study Switch From Abacavir/Lamivudine Fixed Dose Combination Plus Nevirapine Abacavir/Lamivudine/Dolutegravir Virologically Suppressed HIV-1 Infected Adults ( SWAD )</brief_title>
	<detailed_description />
	<mesh_term>Nevirapine</mesh_term>
	<mesh_term>Abacavir</mesh_term>
	<mesh_term>Dideoxynucleosides</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<mesh_term>Dolutegravir</mesh_term>
	<criteria>Patient confirm HIV1 infection ( HIV antibody positive confirmation prior screen ) Age ≥ 18 year Written inform consent Male patient nonpregnant , nonlactating female patient On antiretroviral treatment nevirapine ( 400 mg per day ) plus abacavir/lamivudine 6 month ; Nevirapine 400 mg/day administer either 1 x 200 mg IR x 2/day 2 x 200 mg IR qd 1 x 400 mg XR qd No history prior virologic failure antiretroviral therapy HIV1 RNA &lt; 50 copies/ml 1 year , No major IASUSA nucleoside reverse transcriptase inhibitor integrase inhibitor resistance mutation genotypic test last plasma sample HIV1 RNA &gt; 500 c/mL ( available ) HLAB*5701 negative test Subjects cover Health Insurance Woman childbearing potential without effective contraception method . Pregnant breastfeed woman . Woman expect conceive study period HIV2 coinfection Any prior exposure integrase inhibitor ( ) Plasma HIV1 RNA &gt; 50 c/mL past year Creatinine clearance &lt; 60 ml/mn ( estimate glomerular filtration rate accord MDRD equation ) , Alkaline phosphatase , ASAT ALAT ≥ 5 time upper limit norm ( ULN ) Patient history decompensated liver disease Any major IASUSA mutation confer resistance one reverse transcriptase integrase inhibitor historical plasma genotype available . Any previous genotype result valid , time limit , long original test result document . Mycobacteriosis treatment Malignancy require chemotherapy radiotherapy Positive HBs Ag HCV infection specific treatment ongoing plan study Known hypersensitivity one trial drug , metabolite formulation excipients Concomitant therapy antacid H2 antagonist Contraindicated concomitant treatment Anticipated noncompliance protocol Participation another clinical trial ongoing exclusion period screen Subject legal guardianship incapacitation Subject , opinion investigator , unable complete study period</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>HIV-1 infection</keyword>
	<keyword>Nevirapine</keyword>
	<keyword>Dolutegravir</keyword>
	<keyword>Anti-retroviral agent</keyword>
</DOC>